Pediatric Emergencies Associated with Fever

Emergency Medicine Clinics of North America

Volumn 28, Issue 1, 2010, Pages 67-84

  Claudius, Ilene ^a   Baraff, Larry J ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Emergency department; Fever; Serious bacterial infection

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; ANTITHROMBIN III; C REACTIVE PROTEIN; CEFALEXIN; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; CORTICOTROPIN; COTRIMOXAZOLE; DOXYCYCLINE; DROTRECOGIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN; MENINGOCOCCUS VACCINE; METICILLIN; MINOCYCLINE; PENICILLIN G; PNEUMOCOCCUS VACCINE; RIFAMPICIN;

ABSCESS DRAINAGE; ADRENAL INSUFFICIENCY; ANTIBIOTIC RESISTANCE; BACTERIAL MENINGITIS; CATHETER INFECTION; CHILD HEALTH CARE; CLINICAL EXAMINATION; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; EMERGENCY WARD; FEVER; HAEMOPHILUS INFLUENZAE TYPE B; HERPES SIMPLEX; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HIGH RISK PATIENT; HUMAN; HYPERPYREXIA; INFLUENZA; LABORATORY TEST; MEDICAL ASSESSMENT; MENTAL HEALTH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEISSERIA MENINGITIDIS; PNEUMOCOCCAL INFECTION; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYODERMA; PYREXIA IDIOPATHICA; RECTUM TEMPERATURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SICKLE CELL ANEMIA; STREPTOCOCCUS PNEUMONIAE;

EID: 70450235284     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2009.09.002     Document Type: Review

References (103)

1. Carroll A.E., and Buddenbaum J.L. Malpractice claims involving pediatricians: epidemiology and etiology. Pediatrics 120 1 (2007) 10-17
2. Nager A. Pediatric emergency medicine. In: Baren, Brennan, Brown, et al, editors. Dehydration and Disorders of Sodium Balance. Chapter 110. 2007. p. 782-5.
3. McCarthy P.L., Lembo R.M., Baron M.A., et al. Predictive value of abnormal physical examination findings in ill-appearing and well-appearing febrile children. Pediatrics 76 2 (1985) 167-171
4. Teach S.J., and Fleisher G.R. Efficacy of an observation scale in detecting bacteremia in febrile children three to thirty-six months of age, treated as outpatients. J Pediatr 126 6 (1995) 877-881
5. Silverman B. Practical information. In: Fleisher G.R., Ludwig S., and Henretig F. (Eds). Textbook of pediatric emergency medicine. 5th edition (2006), Lippincott Williams & Williams, Philadelphia 2013
6. Baraff L.J. Management of infants and children 3 to 36 months of age with fever without source. Pediatr Ann 22 8 (1993) 501-504
7. Black S., Shinefield H., Fireman B., et al. Efficacy, safety, and immunogenicity of heptavalent conjugate pneumococcal vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 (2000) 187-195
8. Wilkinson M., Bulloch B., and Smith M. Prevalence of occult bacteremia in children aged 3 to 36 months presenting to the emergency department with fever in the post-pneumococcal conjugate vaccine era. Acad Emerg Med 16 (2008) 1-6
9. Carstairs K.L., Tanen D.A., Johnson A.S., et al. Pneumococcal bacteremia in febrile infants presenting to the emergency department before and after the introduction of the heptavalent pneumococcal vaccine. Ann Emerg Med 49 6 (2007) 772-777
10. Norberg A., Christopher N.C., Ramundo M.L., et al. Contamination rates of blood cultures obtained by dedicated phlebotomy vs intravenous catheter. JAMA 289 6 (2003) 726-729
11. Lee G.M., Fleisher G.R., and Harper M.B. Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis. Pediatrics 108 4 (2001) 835-844
12. Stoll M.L., and Rubin L.G. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine; a study from a children's hospital emergency department and urgent care center. Arch Pediatr Adolesc Med 158 7 (2004) 671-675
13. Issacman D.J., and Burke B. Utility of the serum C-reactive protein for detection of occult bacterial infection in children. Arch Pediatr Adolesc Med 156 (2002) 905-909
14. Maniaci V., Duaber A., Weiss S., et al. Procalcitonin in young febrile infants for the detection of serious bacterial infections. Pediatrics 122 4 (2008) 701-710
15. Dai Y., Foy H.M., Zhu Z., et al. Respiratory rate and signs in roentgenographically confirmed pneumonia among children in China. Pediatr Infect Dis 14 1 (1995) 48-50
16. Murphey C.G., van de Pol A.C., Harper M.B., et al. Clinical predictors of occult pneumonia in the febrile child. Acad Emerg Med 14 3 (2007) 243-249
17. Bachur R., Perry H., and Harper M.B. Occult pneumonias: empiric chest radiographs in febrile children with leukocytosis. Ann Emerg Med 33 2 (1999) 166-173
18. Hoberman A., Chao H.P., Keller D.M., et al. Prevalence of urinary tract infection in febrile infants. J Pediatr 123 1 (1993) 17-23
19. Hoberman A., and Wald E.R. Urinary tract infections in young febrile children. Pediatr Infect Dis J 16 1 (1997) 11-17
20. Committee on quality improvement, subcommittee on urinary tract infection. Practice parameter: the diagnosis, treatment, and evaluation of the initial urinary tract infection in febrile infants and young children. Pediatrics 103 4 Pt 1 (1999) 843-852
21. Whitley R.J., and Kimberlin D.W. Viral encephalitis. Pediatr Rev 20 (1999) 192
22. Caviness A.C., Demmler G.J., Almendarez Y., et al. The prevalence of neonatal herpes simplex virus compared to serious bacterial illness among hospitalized febrile neonates. J Pediatr 153 2 (2008) 164-169
23. Meyer M.H., Johnson R.T., Crawford I.P., et al. Central nervous system syndromes of viral etiology. Am J Med 29 (1960) 334-347
24. Whitley R.J. Herpes simplex encephalitis: adolescents and adults. Antiviral Res 71 (2006) 141-148
25. De Tiege X., Rozenberg F., Des Portes V., et al. Herpes simplex encephalitis relapses in children: differentiation of two neurologic entities. Neurology 61 (2003) 241-243
26. Kennedy P.G.E., and Chaudhuri A. Herpes simplex encephalitis. J Neurol Neurosurg Psychiatr 73 (2002) 237-238
27. Steiner I., Kennedy P.G., and Pachner A.R. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol 6 11 (2007) 1015-1028
28. Teixeira J., Zimmerman R.A., Haselgrove J.C., et al. Diffusion imaging in pediatric central nervous system infections. Neuroradiology 43 (2001) 1031-1039
29. Eeg-Olofsson O., Bergstrom T., Andermann E., et al. Herpesviral DNA in brain tissue from patients with temporal lobe epilepsy. Acta Neurol Scand 109 3 (2004) 169-174
30. Whitley R.J. Therapeutic advances for severe and life-threatening herpes simplex virus infections. In: Lopez C., and Roizman B. (Eds). Human herpes virus infections (1986), Raven Press, New York p.153-64
31. Elbers J.M., Bitnun A., Richardson S.E., et al. A 12-year prospective study of childhood herpes simplex encephalitis: is there a broader spectrum of disease?. Pediatrics 119 (2007) e399-e407
32. Purcell K., and Fergie J.E. Exponential increase in community-acquired methicillin-resistant Staphylococcus aureus infections in South Texas children. Pediatr Infect Dis J 21 10 (2002) 988-989
33. Castaldo E.T., and Yang E.Y. Severe sepsis attributable to community-associated methicillin-resistant Staphylococcus aureus: an emerging fatal problem. Am Surg 73 (2007) 684-687
34. Zaoutis T.E., Toltzis P., Chu J., et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infections: 2001-2003. Pediatr Infect Dis J 25 4 (2006) 343-348
35. Gonzalez B.E., and Kaplan S.L. Severe staphylococcal infections in children. Pediatr Ann 37 10 (2008) 686-693
36. Fridkin S.K., Hageman J.C., Morrison M., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352 (2005) 1436-1444
37. Paintsil E. Pediatric community-acquired methicillin-resistant Staphylococcus aureus infection and colonization: trends and management. Curr Opin Pediatr 19 (2007) 75-82
38. Lee M.C., Rios A.M., Aten M.F., et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 23 2 (2004) 123-127
39. Laupland K.B., Ross T., and Gregson D.B. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2005. J Infect Dis 198 3 (2008) 336-343
40. Denniston S., and Riordan F.A. Staphylococcus aureus bacteraemia in children and neonates: a 10 year retrospective review. J Infect 53 (2006) 387-393
41. Cohen-Wolkowiez M., Benjamin D.K., Fowler V.G., et al. Mortality and neurodevelopment after Staphylococcus aureus bacteremia in infants. Pediatr Infect Dis J 26 12 (2007) 1159-1161
42. Gonzalez B.E., Hulten K.G., Dishop M.K., et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 41 (2005) 583-590
43. Woodward A.L., and Sundel R.P. Rheumatologic emergencies. In: Fleisher G.R., Ludwig S., and Henretig F. (Eds). Textbook of pediatric emergency medicine. 5th edition (2006), Lippincott Williams & Williams, Philadelphia 1305-1310
44. Manci E.A., Culberson D.E., Yang Y.M., et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol 123 2 (2003) 359-365
45. Halasa N.B., Shankar S.M., Talbot T.R., et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 44 11 (2007) 1428-1433
46. Wilimas J.A., Flynn P.M., Harris S., et al. A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med 329 7 (1993) 472-476
47. Kirsch E.A., Barton R.P., Kitchen L., et al. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 15 11 (1996) 967-979
48. Rosenstein N.E., Perkins B.A., Stephens D.S., et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 180 (1999) 1894-1901
49. Singh J., and Arrieta A. Management of meningococcemia. Indian J Pediatr 71 (2007) 909-913
50. Brandtzaed P., Dahle J.S., and Hoiby E.A. The occurrence and features of hemorrhagic skin lesions in 115 cases of systemic meningococcal disease. NIPH Ann 6 (1983) 183-190
51. Lodder M.C., Schildkamp R.L., Biljmer H.A., et al. Prognostic indicators of the outcome of meningococcal disease: a study of 562 patients. J Med Microbiol 45 (1996) 16-20
52. Stephans D.S., Greenwood B., and Brantzaeg P. Epidemic meningitis, meningococceamia, and Neisseria meningitidis. Lancet 369 (2007) 2196-2210
53. Herrera R., Hobar P.C., and Ginsburg C.M. Surgical intervention for the complications of meningococcal-induced purpura fulminans. Pediatr Infect Dis J 13 (1994) 734-737
54. Thompson M.J., Ninis N., Perera R., et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 367 (2006) 397-403
55. Inkelis S.H., O'Leary D., Wang V., et al. Extremity pain and refusal to walk in children with invasive meningococcal disease. Pediatrics 110 (2002) e3
56. Wylie P.A., Stevens D., Drake W., et al. Epidemiology and clinical management of meningococcal disease in west Gloucestershire: retrospective, population based study. BMJ 315 (1997) 774-779
57. Perkins M.D., Mirrett S., and Reller L.B. Rapid bacterial antigen detection is not clinically useful. J Clin Microbiol 33 6 (1995) 1486-1491
58. Flexner S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 17 (1913) 553-576
59. White B., Livingstone W., Murphy C., et al. Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
60. Levi M., de Jonge E., and van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med 36 (2004) 41-49
61. Afshari A., Wetterslev J., Brok J., et al. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 335 (2007) 1248-1251
62. Annane D., Sébille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 7 (2002) 862-871
63. Sprung C.L., Annane D., Keh D., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 358 2 (2008) 111-124
64. Russell J.A., Walley K.R., Gordon A.C., et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 37 3 (2009) 811-818
65. Wu H.M., Harcourt B.H., Hatcher C.P., et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med 360 9 (2009) 886-892
66. Pantell R.H., Newman T.B., Bernzweig J., et al. Management and outcomes of care of fever in early infancy. JAMA 291 10 (2004) 1203-1212
67. Kadish H.A., Loveridge B., Tobey J., et al. Applying outpatient protocols in febrile infants 1-28 days of age: can the threshold be lowered?. Clin Pediatr 39 (2000) 81-88
68. Baskin M.N., O'Fourke E.J., and Fleisher G.R. Outpatient treatment of febrile infants 28 to 89 days with intramuscular administration of ceftriaxone. J Pediatr 120 (1992) 22-27
69. Baker M.D., Bell L.M., and Avner J.R. Outpatient management without antibiotics of fever in selected infants. N Engl J Med 329 (1993) 1437-1441
70. Jaskiewicz J.A., McCarthy C.A., Richardson A.C., et al. Febrile infants at low risk for serious bacterial infections- an appraisal of the Rochester criteria and implications for management. Pediatrics 94 (1994) 390-396
71. Baraff L.J. Management of infants and young children with fever without source. Pediatr Ann 37 10 (2008) 673-679
72. Hoberman A., Wald E.R., Hickey R.W., et al. Oral versus intravenous therapy for urinary tract infections in young febrile children. Pediatrics 104 1 Pt 1 (1999) 79-86
73. Baker M.D., and Bell L.M. Unpredictability of serious bacterial illness in febrile infants from birth to 1 month of age. Arch Pediatr Adolesc Med 153 (1999) 508-511
74. Ferrera P.C., Bartfield J.M., and Snyder H.S. Neonatal fever: utility of Rochester criteria in determining low risk for serious bacterial infections. Am J Emerg Med 15 (1997) 299-302
75. Wu W., Chen H., Chung P., et al. Ambulatory care of selected febrile outpatient neonates unlikely to have bacterial infections. Int Pediatr 19 1 (2004) 52-56
76. Chiu C., Lin T., and Bullard M. Identification of febrile neonates unlikely to have bacterial infections. Pediatr Infect Dis J 16 1 (1997) 59-63
77. Brown L., Shaw T., Moynihan J.A., et al. Investigation of afebrile neonates with a history of fever. CJEM 6 5 (2004) 343-348
78. Bonadio W.A., Hegenbarth M., and Zachariason M. Correlating reported fever in young infants with subsequent temperature patterns and rate of serious bacterial infections. Pediatr Infect Dis J 9 3 (1990) 158-160
79. Levine D.A., Platt S.L., Dayan P.S., et al. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. Pediatrics 113 (2004) 1728-1734
80. Bilavsky E., Shouval D.S., Yarden-Bilavsky H., et al. A prospective study of the risk for serious bacterial infections in hospitalized febrile infants with or without bronchiolitis. Pediatr Infect Dis J 27 3 (2008) 269-270
81. Smitherman H.F., Caviness A.C., and Macias C.G. Retrospective review of serious bacterial infections in infants who are 0 to 36 months and have influenza A infection. Pediatrics 115 3 (2005) 710-718
82. Sakran W., Makary H., Colodner R., et al. Acute otitis media in infants less than three moths of age: clinical presentation, etiology and concomitant diseases. Int J Pediatr Otorhinolaryngol 70 4 (2006) 613-617
83. Van der Jagt EW. Fever of unknown origin. In: AAP textbook of pediatric care, 2008: Available at: http://www.pediatriccareonline.org/pco/ub/pview/AAP-Textbook-of-Pediatric-Care/394181/all/Chapter_181:_Fever?q=occult%20bacteremia. Accessed October 16, 2009.
84. Berezin E.N., and Iazzetti M.A. Evaluation of the incidence of occult bacteremia among children with fever of unknown origin. Braz J Infect Dis 10 6 (2006) 396-399
85. Tolia J., and Smith L.G. Fever of unknown origin: historical and physical clues to making the diagnosis. Infect Dis Clin North Am 21 (2007) 917-936
86. Lohr J.A., and Hendley J.O. Prolonged fever of unknown origin: a record of experiences with 54 childhood patients. Clin Pediatr 16 (1977) 768-773
87. Akpede G.O., and Akenzua G.I. Management of children with prolonged fever of unknown origin and difficulties in the management of fever of unknown origin in children in developing countries. Paediatr Drugs 3 4 (2001) 247-262
88. Gaeta G., Fusco F., and Nardiello S. Fever of unknown origin: a systemic review of the literature for 1995-2004. Nucl Med Commun 27 (2006) 205-211
89. Mackowiak P., and Durack D. Fever of unknown origin. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Mandell, Douglas and Bennett's Principles and Practice of Infectious Disease. 6th edition (2005), Elsevier, Philadelphia (PA) 718-729
90. Talano J.M., and Kazt B.Z. Long-term follow-up of children with fever of unknown origin. Clin Pediatr 39 (2000) 715
91. Miller L.C., Sisson B.A., Tucker L.B., et al. Prolonged fevers of unknown origin in children: patterns of presentation and outcome. J Pediatr 12 (1996) 419-423
92. Trautner B.W., Caviness C., Gerlacher G.R., et al. Prospective evaluation of the risk of serious bacterial infection in children who present to the emergency department with hyperpyrexia. Pediatrics 118 (2006) 34-40
93. McCarthy P.L., and Dolan Jr. T.F. Hyperpyrexia in children. Eight-year emergency room experience. Am J Dis Child 130 8 (1976) 849-851
94. Jamuma R., Srinivasan S., and Hariah B.N. Factors predicting occult bacteremia in young children. Indian J Pediatr 67 10 (2000) 709
95. McCarthy P.L., Bass J.W., Steele R.W., et al. Antimicrobial treatment of occult bacteremia: a multicenter cooperative study. Pediatr Infect Dis J 12 (1993) 466-473
96. Coffin S.E., Zaoutis T.E., Rosenquist A.B., et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics 119 (2007) 740-748
97. Fratino G., Molinari A.C., Parodi S., et al. Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Ann Oncol 16 (2005) 1510-1513
98. Cesaro S., Corro R., Pelosin A., et al. A prospective survey on incidence and outcome of Broviac/Hickman catheter-related complications in pediatric patients affected by hematologic and oncologic diseases. Ann Hematol 83 (2004) 183-188
99. Gorelick M.H., Owen W.C., Seibel N.L., et al. Lack of association between neutropenia and the incidence of bacteremia associated with indwelling central venous catheters in febrile pediatric cancer patients. Pediatr Infect Dis J 10 (1991) 506-510
100. Sinom A., Bode U., and Beutel K. Diagnosis and treatment of catheter-related infections in paediatric oncology: an update. Clin Microbiol Infect 12 (2006) 606-620
101. Robinson J.L. Sensitivity of a blood culture drawn through a single lumen of a multilumen, long-term, indwelling, central venous catheter in pediatric oncology patients. J Pediatr Hematol Oncol 24 1 (2002) 72-74
102. Shah S.S., Downes K.J., Elliot M.R., et al. How long does it take to "rule out" bacteremia in children with central venous catheters. Pediatrics 121 (2008) 135-141
103. Caterino J.M., Scheatzle M.D., and D'Antonio J.A. Descriptive analysis of 258 emergency department visits by spina bifida patients. Ann Emerg Med 38 4 (2001) S74-S75